Study guide
5.5 Medication Reconciliation & Integrating the Medical Record
Certified Asthma Educator AE-C
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Exam Overview
1.1 About the AE-C Examination 1.2 How to Use This Study Guide
2 Chapter 2: Anatomy, Physiology & Airway Pathophysiology
2.1 Normal vs. Asthmatic Airway Architecture 2.2 Cellular Inflammation, Mediators & Airway Remodeling 2.3 Bronchial Hyperresponsiveness & Airflow Obstruction Mechanics
3 Chapter 3: Triggers, Exposures & Phenotypes
3.1 Aeroallergens & Allergic Sensitization Mechanisms 3.2 Non-Allergic Irritants & Environmental Airborne Hazards 3.3 Respiratory Infections, Exercise & Physiological Stressors 3.4 Asthma Phenotypes, Endotypes & Lifespan Variations 3.5 Genetics, Family History & Early-Life Determinants
4 Chapter 4: Comorbidities, Medications & Asthma Mimics
4.1 Upper Airway Diseases & Gastroesophageal Reflux 4.2 Systemic Comorbidities, Obesity & Adverse Drug Reactions 4.3 Differential Diagnosis & Major Asthma Mimics
5 Chapter 5: Clinical History & Physical Assessment
5.1 Comprehensive Asthma History & Risk Stratification 5.2 Physical Examination, Auscultation & Atopic Stigmata 5.3 Acute Exacerbation Severity Triage & Life-Threatening Red Flags 5.4 Criteria for Specialist Referral & Advanced Consultation 5.5 Medication Reconciliation & Integrating the Medical Record
6 Chapter 6: Diagnostic Testing & Pulmonary Function
6.1 Spirometry Principles, Maneuvers & ATS/ERS Quality Criteria 6.2 Bronchodilator Reversibility Testing Protocols & Interpretation 6.3 Peak Expiratory Flow Monitoring & Personal Best Determination 6.4 FeNO, Methacholine Challenge & Allergy Testing Modalities
7 Chapter 7: Severity, Control & Psychosocial Evaluation
7.1 Asthma Severity Classification (NHLBI EPR-3 & GINA) 7.2 Asthma Control Assessment Tools & Validated Questionnaires 7.3 Health Literacy, Educational Needs Assessment & Plain Language Principles 7.4 Psychosocial, Cultural & Family Dynamics in Self-Management
8 Chapter 8: Reliever Medications & Bronchodilators
8.1 Short-Acting Beta-2 Agonists (SABAs) & Cellular Mechanisms 8.2 SABA Overuse, Paradoxical Hyperresponsiveness & Safety Warnings 8.3 Short-Acting Muscarinic Antagonists (SAMAs) & Acute Adjunctive Therapy 8.4 SMART/MART & Anti-Inflammatory Reliever (AIR) Regimens
9 Chapter 9: Inhaled Corticosteroids & Combination Therapies
9.1 Inhaled Corticosteroids: Pharmacology, Potency & Dosing 9.2 ICS Adverse Effects, Systemic Safety & Dispelling Steroid Phobia 9.3 Long-Acting Beta-2 Agonists & Fixed-Dose Combination Inhalers 9.4 Stepwise Pharmacotherapy Guidelines (Age-Stratified Step-Up & Step-Down)
10 Chapter 10: Additional Controllers & Biologic Therapies
10.1 Leukotriene Modifiers & 5-Lipoxygenase Inhibitors 10.2 Long-Acting Muscarinic Antagonists (LAMAs) & Alternative Controllers 10.3 Monoclonal Antibodies & Biologic Therapies for Severe Asthma 10.4 Systemic Corticosteroids, Adrenal Safety & Immunizations 10.5 Allergen Immunotherapy, Intranasal Therapy & Treating Comorbidities
11 Chapter 11: Inhalation Devices & Delivery Mechanics
11.1 Pressurized Metered-Dose Inhalers (pMDIs) & Valved Holding Chambers 11.2 Dry Powder Inhalers (DPIs): Mechanics, Resistance & Technique 11.3 Soft Mist Inhalers (SMIs) & Small-Volume Nebulizers (SVNs) 11.4 Device Selection Algorithm, Patient Capabilities & Technique Assessment 11.5 Over-the-Counter, Alternative & Complementary Therapies
12 Chapter 12: Environmental Control & Behavioral Interventions
12.1 Evidence-Based Indoor Allergen Mitigation & Integrated Pest Management 12.2 Tobacco Cessation, Electronic Nicotine Systems & Irritant Elimination 12.3 Exercise-Induced Bronchoconstriction (EIB) Management & Sports Participation 12.4 Behavioral Counseling, Motivational Interviewing & Adherence Enhancement 12.5 Social, Economic & Substance-Use Barriers to Self-Management
13 Chapter 13: Action Plans, Exacerbations & Continuing Care
13.1 Written Asthma Action Plans & the Traffic-Light Zone System 13.2 School, Workplace & Childcare Action Plans 13.3 Home & Outpatient Acute Exacerbation Protocols 13.4 Periodic Reevaluation, Step-Down & Post-Discharge Follow-Up 13.5 Designing the Individualized Self-Management Education Plan 13.6 Coaching Decision-Making, Confidence & Documenting Mastery
14 Chapter 14: Program Needs Assessment & Implementation
14.1 Epidemiological Analysis & Community Needs Assessment 14.2 Evidence-Based Asthma Interventions & CDC EXHALE Strategies 14.3 Program Design, Multidisciplinary Staffing & Operational Workflows
15 Chapter 15: Evaluation, Ethics, Quality & Health Systems
15.1 Legal, Ethical, HIPAA/FERPA & Clinical Documentation Standards 15.2 Program Evaluation, CQI Methodologies & Outcome Metrics 15.3 Interprofessional Partnerships, Advocacy & Reimbursement Pathways
5.5 Medication Reconciliation & Integrating the Medical Record
Key Takeaways Explain This Topic AI
A brown-bag review — having the patient physically bring every inhaler, tablet, eye drop, supplement, and cream to the visit — surfaces duplications, expired devices, and hidden beta-blockers that a verbal medication list reliably misses.
The Asthma Medication Ratio divides controller fills by total asthma medication fills; a ratio below 0.50 flags reliever-dominant, under-controlled asthma and is the basis of the NCQA HEDIS quality measure.
Dose counters and pharmacy refill dates give objective adherence data that patient self-report consistently overstates.
Topical ophthalmic beta-blockers, over-the-counter NSAIDs, and herbal products are the three categories patients most often omit when asked to list their medications, and each can precipitate bronchospasm.
Chart integration means reconciling five streams — prior spirometry, exacerbation and admission history, oral corticosteroid bursts, prescription fill records, and specialist notes — before designing any education plan.
Last updated: September 2026
5.5 Medication Reconciliation & Integrating the Medical Record
Quick Answer: Ask patients to bring every product they put in or on their body — inhalers, tablets, eye drops, nasal sprays, creams, supplements, and teas — rather than reciting a list. Then reconcile that physical inventory against pharmacy fill records, dose counters, and the chart . The single most useful objective adherence metric is the Asthma Medication Ratio (AMR) : controller fills divided by total asthma medication fills, where below 0.50 signals reliever-dominant, poorly controlled asthma .
Two Detailed Content Outline tasks sit behind this section: soliciting information about medications, alternative and complementary therapies, and over-the-counter products; and integrating information from the medical record into the assessment. Both are routinely skipped, and both routinely change the plan.
The Brown-Bag Review
Verbal medication lists fail predictably. Patients recite what they were prescribed , not what they take ; they omit anything they do not classify as medication; and they cannot name devices they use daily.
Protocol:
At scheduling, instruct the patient to bring every container — prescription bottles, all inhalers and spacers, eye drops, nasal sprays, topical creams, vitamins, herbal products, and any teas or remedies used for breathing.
Lay the products out. Ask about each one: "Tell me how you actually use this one." Never ask "Do you take this as prescribed?", which invites a socially desirable answer.
Check the dose counter on every inhaler and the expiration date on every device.
Ask separately about the three categories patients systematically omit.
Commonly omitted category Why it is omitted Asthma consequence
Ophthalmic beta-blockers (timolol, levobunolol) Patients do not classify eye drops as systemic medication Non-selective beta-blockade absorbed through the nasolacrimal duct, bypassing first-pass metabolism; can precipitate refractory bronchospasm
Over-the-counter NSAIDs and hidden combination products Considered "not real medicine"; aspirin and ibuprofen are buried in cold, sinus, and menstrual remedies Life-threatening reactions in aspirin-exacerbated respiratory disease
Herbal, nutritional, and complementary products Assumed harmless or feared to invite judgment Unknown potency and contaminants; some interact with theophylline or corticosteroids; delay of effective therapy
Non-judgmental phrasing that works: "Most people miss doses — in the last week, how many days do you think you missed your controller?" Normalizing the behavior before asking the number produces a materially more honest answer than a yes/no adherence question.
Objective Adherence Data
Self-reported adherence overstates actual use consistently. Four objective sources close the gap.
Source What it shows Limitation
Pharmacy refill records Whether medication was ever dispensed and how often Dispensing is not ingestion or inhalation
Dose counters Actuations remaining versus expected Absent on some older devices; can be defeated by shaking or test-firing
- Canister count over time SABA canisters per year is the classic risk marker Requires accurate fill history
- Electronic inhaler monitors Timestamped actuation data Cost and availability limit routine use
The Asthma Medication Ratio (AMR) AMR = controller medication fills controller fills + reliever fills \text{AMR} = \frac{\text{controller medication fills}}{\text{controller fills} + \text{reliever fills}} AMR = controller fills + reliever fills controller medication fills
AMR of 0.50 or above is the threshold used by the NCQA HEDIS Asthma Medication Ratio quality measure and is associated with fewer emergency department visits and hospitalizations.
AMR below 0.50 means the patient's asthma pharmacy footprint is dominated by rescue medication — the pharmacologic signature of uncontrolled disease regardless of what the patient reports.
Worked example. Over 12 months a patient filled 2 ICS-LABA inhalers and 7 albuterol inhalers.
AMR = 2 ÷ (2 + 7) = 0.22 . Well below 0.50, and the 7 SABA canisters independently exceed the ≥3 canisters-per-year threshold for elevated exacerbation and asthma-death risk. Two independent signals point at the same conclusion before the patient has said a word about symptoms.
Exam Trap: A high AMR does not prove good technique. A patient may fill controller medication faithfully and still deposit almost none of it in the lungs. Refill data answers "is the medication in the house?" ; return demonstration answers "is the medication in the lungs?" Both are required.
Integrating the Medical Record
The Detailed Content Outline lists the chart elements explicitly: family, clinical, and past medical history; physical examination; vital sign findings; laboratory, pulmonary function, and radiological results; current and past therapies; and diagnostic interpretations of objective measures. In practice, five streams change the education plan before it is drafted.
Chart stream What to extract How it changes the plan
Prior spirometry and PEF Best-ever FEV1 and personal best PEF; trend across years Establishes the achievable target and whether fixed obstruction has developed; prevents building action-plan zones on an artificially low "personal best" recorded during a flare
Exacerbation and utilization history Emergency visits, admissions, ICU stays, any intubation Any prior intubation or ICU admission permanently classifies the patient as high-risk and mandates a written action plan plus close follow-up
Oral corticosteroid bursts Number of courses in the past 12 months Two or more bursts per year signals inadequate controller therapy and independently predicts future exacerbations
Prescription fill history AMR, SABA canisters per year, gaps in controller supply Distinguishes a therapy problem from an adherence problem from an access problem
Specialist and allergy results Skin prick or specific IgE results, FeNO, eosinophil counts, prior consultations Determines which allergens actually warrant environmental remediation — remediating a non-sensitized allergen wastes limited household money
- The Reconciliation Sequence 1. Brown-bag inventory ─► what the patient physically possesses
- │
- 2. Fill history / AMR ─► what the pharmacy actually dispensed
- │
- 3. Dose counters ─► what was actuated
- │
- 4. Chart review ─► what was prescribed, and what happened clinically
- │
- ▼
Discrepancies drive the education plan:
- Possesses but does not fill ─► cost, access, or transportation barrier
- Fills but does not actuate ─► belief, forgetfulness, or steroid phobia
- Actuates but no clinical benefit ─► device technique failure or wrong diagnosis
- Possesses a contraindicated drug ─► immediate safety escalation to the prescriber
Scope reminder: The asthma educator reconciles, documents, and reports. Discovering that a patient with asthma is using timolol eye drops or a non-selective oral beta-blocker calls for prompt communication with the prescribing clinician — the educator does not discontinue, substitute, or adjust prescribed therapy independently.